肿瘤出芽在肝细胞癌中的分子机制及临床应用价值

张宏斌; 谭凯; 杨振宇; 贾生雄; 杜锡林

doi:10.12449/JCH250524

肿瘤出芽在肝细胞癌中的分子机制及临床应用价值

DOI: 10.12449/JCH250524

张宏斌^{1, 2},
谭凯¹,
杨振宇¹,
贾生雄¹,
杜锡林^1, , ,

1.
空军军医大学第二附属医院普通外科，西安 710038
2.
中国人民解放军63600部队医院普通外科，兰州 732750

基金项目:

西安市科技计划项目 (23YXYJ0154);

唐都医院学科助推计划 (2024JSYX019)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：张宏斌负责确定选题，资料分析，撰写论文；谭凯、杨振宇参与文章审阅，修改论文；贾生雄负责文献检索，收集资料；杜锡林负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
杜锡林， duxl0705@fmmu.edu.cn （ORCID： 0000-0002-0435-5488）

计量
- 文章访问数: 86
- HTML全文浏览量: 38
- PDF下载量: 10
- 被引次数: 0
出版历程
- 收稿日期: 2024-11-28
- 录用日期: 2025-01-22
- 出版日期: 2025-05-25

Molecular mechanisms and clinical applications of tumor budding in hepatocellular carcinoma

1.
Department of General Surgery，The Second Affiliated Hospital of Air Force Medical University，Xi’‍an 710038，China
2.
Department of General Surgery，63600 Army Hospital of PLA，Lanzhou 732750，China

Research funding:

The Science and Technology Project of Xi’an (23YXYJ0154);

Tangdu Hospital Discipline Promotion Project (2024JSYX019)

More Information

Corresponding author: DU Xilin， duxl0705@fmmu.edu.cn （ORCID： 0000-0002-0435-5488）

摘要

摘要: 肿瘤出芽是一种存在于多种实体癌中的特殊病理形态学表现。近年来，肿瘤出芽被认为是肿瘤侵袭和转移的重要生物学特征，成为研究肿瘤进展的新焦点。尽管已有研究探讨了肿瘤出芽在多种肿瘤中的作用，但其在肝细胞癌领域的相关研究仍然相对较少。本综述旨在系统地回顾肝细胞癌中肿瘤出芽的研究进展，重点分析肿瘤出芽机制、出芽与肿瘤进展的关系及其在预后评估中的潜在应用，力求为肝细胞癌的早期诊断及治疗提供新的思路和策略。
- 癌，肝细胞 /
- 肿瘤出芽 /
- 预后
Abstract: Tumor budding is a distinct pathomorphological feature observed in various types of solid tumor. In recent years， tumor budding has been recognized as an important biological feature associated with tumor invasion and metastasis， and it has become a new focus in the research on tumor progression. Although studies have explored the role of tumor budding in different types of tumor， there are studies in the field of hepatocellular carcinoma （HCC）. This article systematically reviews the research advances in tumor budding in HCC， with a focus on the mechanism of tumor budding， the association between tumor budding and tumor progression， and the potential application of tumor budding in prognostic assessment， in order to provide new insights and strategies for the early diagnosis and treatment of HCC.
- Carcinoma， Hepatocellular /
- Tumor Budding /
- Prognosis

HTML全文

表 1 ITBCC肿瘤出芽分级标准

Table 1. ITBCC tumor budding grading criteria

肿瘤出芽数量	肿瘤出芽分级
0～4个	低级别肿瘤出芽（BD1）
5～9个	中级别肿瘤出芽（BD2）
≥10个	高级别肿瘤出芽（BD3）
注：使用20倍物镜在HE染色标本上的“热点”处计数肿瘤出芽数量，然后标准化为0.785 mm²的视野面积。

下载: 导出CSV

参考文献(44)

[1]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74( 3): 229- 263. DOI: 10.3322/caac.21834.
[2]	PRASAD D, NGUYEN MH. Epidemiology, pathogenesis, diagnosis, surveillance, and management of hepatocellular carcinoma associated with vascular liver disease[J]. Kaohsiung J Med Sci, 2021, 37( 5): 355- 360. DOI: 10.1002/kjm2.12368.
[3]	TÜMEN D, HEUMANN P, GÜLOW K, et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma[J]. Biomedicines, 2022, 10( 12): 3202. DOI: 10.3390/biomedicines10123202.
[4]	TURAJLIC S, SWANTON C. Metastasis as an evolutionary process[J]. Science, 2016, 352( 6282): 169- 175. DOI: 10.1126/science.aaf2784.
[5]	LUGLI A, ZLOBEC I, BERGER MD, et al. Tumour budding in solid cancers[J]. Nat Rev Clin Oncol, 2021, 18( 2): 101- 115. DOI: 10.1038/s41571-020-0422-y.
[6]	HASE K, SHATNEY C, JOHNSON D, et al. Prognostic value of tumor“budding” in patients with colorectal cancer[J]. Dis Colon Rectum, 1993, 36( 7): 627- 635. DOI: 10.1007/BF02238588.
[7]	REGMI SM, REGMI P, PAUDYAL A, et al. Tumor budding is associated with poor prognosis and clinicopathologic factors in esophageal carcinoma: A meta-analysis[J]. Eur J Surg Oncol, 2024, 50( 12): 108668. DOI: 10.1016/j.ejso.2024.108668.
[8]	OKCU O, ÖZTÜRK Ç, ŞEN B, et al. Tumor Budding is a reliable predictor for death and metastasis in invasive ductal breast cancer and correlates with other prognostic clinicopathological parameters[J]. Ann Diagn Pathol, 2021, 54: 151792. DOI: 10.1016/j.anndiagpath.2021.151792.
[9]	GÜRÇAY N, ACAR LN, ÜNAL TDK, et al. High grade tumor budding is associated with poor survival in pathologic stage I lung adenocarcinoma[J]. Ann Diagn Pathol, 2023, 66: 152188. DOI: 10.1016/j.anndiagpath.2023.152188.
[10]	KARAMITOPOULOU E, GLOOR B. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Reply to comment[J]. Eur J Cancer, 2013, 49( 10): 2458- 2459. DOI: 10.1016/j.ejca.2013.03.028.
[11]	KEMI N, ESKURI M, IKÄLÄINEN J, et al. Tumor budding and prognosis in gastric adenocarcinoma[J]. Am J Surg Pathol, 2019, 43( 2): 229- 234. DOI: 10.1097/PAS.0000000000001181.
[12]	KAIRALUOMA V, KEMI N, POHJANEN VM, et al. Tumour budding and tumour-stroma ratio in hepatocellular carcinoma[J]. Br J Cancer, 2020, 123( 1): 38- 45. DOI: 10.1038/s41416-020-0847-1.
[13]	JIANG D, XU SS, ZHANG CP, et al. Association between the expression levels of ADAMTS16 and BMP2 and tumor budding in hepatocellular carcinoma[J]. Oncol Lett, 2023, 25( 6): 256. DOI: 10.3892/ol.2023.13842.
[14]	BERG KB, SCHAEFFER DF. Tumor budding as a standardized parameter in gastrointestinal carcinomas: More than just the colon[J]. Mod Pathol, 2018, 31( 6): 862- 872. DOI: 10.1038/s41379-018-0028-4.
[15]	ALMANGUSH A, SALO T, HAGSTRÖM J, et al. Tumour budding in head and neck squamous cell carcinoma- a systematic review[J]. Histopathology, 2014, 65( 5): 587- 594. DOI: 10.1111/his.12471.
[16]	ZLOBEC I, LUGLI A. Tumour budding in colorectal cancer: Molecular rationale for clinical translation[J]. Nat Rev Cancer, 2018, 18( 4): 203- 204. DOI: 10.1038/nrc.2018.1.
[17]	NIRANJAN KC, RAJ M, HALLIKERI K. Prognostic evaluation of tumour budding in oral squamous cell carcinoma: Evidenced by CD44 expression as a cancer stem cell marker[J]. Pathol Res Pract, 2023, 251: 154883. DOI: 10.1016/j.prp.2023.154883.
[18]	ALMAYOUF F. Tumor budding in upper gastrointestinal carcinomas: A systematic review and meta-analysis[J]. Cureus, 2024, 16( 9): e70422. DOI: 10.7759/cureus.70422.
[19]	KOVEITYPOUR Z, PANAHI F, VAKILIAN M, et al. Signaling pathways involved in colorectal cancer progression[J]. Cell Biosci, 2019, 9: 97. DOI: 10.1186/s13578-019-0361-4.
[20]	SUN JY, YIN C, LI J. Research progress on pathways related to proliferation and metastasis of hepatocellular carcinoma[J]. Clin J Med Offic, 2024, 52( 9): 982- 985. DOI: 10.16680/j.1671-3826.2024.09.29. 孙嘉钰, 尹畅, 李京. 肝细胞癌增殖与转移相关通路研究进展[J]. 临床军医杂志, 2024, 52( 9): 982- 985. DOI: 10.16680/j.1671-3826.2024.09.29.
[21]	HADDAD TS, van den DOBBELSTEEN L, ÖZTÜRK SK, et al. Pseudobudding: Ruptured glands do not represent true tumor buds[J]. J Pathol, 2023, 261( 1): 19- 27. DOI: 10.1002/path.6146.
[22]	SHAKHPAZYAN N, MIKHALEVA L, BEDZHANYAN A, et al. Cellular and molecular mechanisms of the tumor stroma in colorectal cancer: Insights into disease progression and therapeutic targets[J]. Biomedicines, 2023, 11( 9): 2361. DOI: 10.3390/biomedicines11092361.
[23]	ROGERS AC, WINTER DC, HEENEY A, et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer[J]. Br J Cancer, 2016, 115( 7): 831- 840. DOI: 10.1038/bjc.2016.274.
[24]	BOSCH SL, TEERENSTRA S, de WILT JH, et al. Predicting lymph node metastasis in pT1 colorectal cancer: A systematic review of risk factors providing rationale for therapy decisions[J]. Endoscopy, 2013, 45( 10): 827- 834. DOI: 10.1055/s-0033-1344238.
[25]	KAUNDIYAL S, CHANDRA S, ARORA A. Study of tumor budding and its association with clinicopathological parameters in breast carcinoma[J]. Rev Assoc Med Bras(1992), 2024, 70( 7): e20240173. DOI: 10.1590/1806-9282.20240173.
[26]	VASUDEVAN S, KANNAN K, RAGHAVAN AV, et al. Analyzing tumor budding scores in invasive breast carcinoma: A tertiary care center study in south India[J]. J Pharm Bioallied Sci, 2024, 16( Suppl 2): S1850- S1853. DOI: 10.4103/jpbs.jpbs_910_23.
[27]	YAAGOUBI S EL, ZARYOUHI M, BENMAAMAR S, et al. Prognostic impact of tumor budding on Moroccan gastric cancer patients[J]. Clin Pathol, 2023, 16: 2632010 X 231184329. DOI: 10.1177/2632010X231184329.
[28]	RATHOD GB, DESAI KN, SHRIVASTAVA A, et al. Correlation of tumor budding with known clinicopathological, histomorphological and hormonal receptor status in patients with invasive breast carcinoma[J]. Cureus, 2022, 14( 9): e29637. DOI: 10.7759/cureus.29637.
[29]	KUMARGURU BN, RAMASWAMY AS, SHAIK S, et al. Tumor budding in invasive breast cancer- An indispensable budding touchstone[J]. Indian J Pathol Microbiol, 2020, 63( Supplement): S117- S122. DOI: 10.4103/IJPM.IJPM_731_18.
[30]	de ASSIS EM, RODRIGUES M, VIEIRA JC, et al. Lymphatic vascular density, the expression of podoplanin and tumor budding in oral squamous cell carcinoma[J]. Head Neck Pathol, 2023, 17( 2): 371- 382. DOI: 10.1007/s12105-022-01511-z.
[31]	ASSIS EM, RODRIGUES M, VIEIRA JC, et al. Microvascular density and tumor budding in oral squamous cell carcinoma[J]. Med Oral Patol Oral Cir Bucal, 2023, 28( 2): e174- e182. DOI: 10.4317/medoral.25640.
[32]	MAYER P, HAUSEN A, STEINLE V, et al. The radiomorphological appearance of the invasive margin in pancreatic cancer is associated with tumor budding[J]. Langenbeck’s Arch Surg, 2024, 409( 1): 167. DOI: 10.1007/s00423-024-03355-3.
[33]	WEI L, DELIN Z, KEFEI Y, et al. A classification based on tumor budding and immune score for patients with hepatocellular carcinoma[J]. Oncoimmunology, 2019, 9( 1): 1672495. DOI: 10.1080/2162402X.2019.1672495.
[34]	ZHOU B, ZONG S, ZHONG W, et al. Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins[J]. Oncogene, 2020, 39( 7): 1527- 1542. DOI: 10.1038/s41388-019-1082-1.
[35]	UNAL B, CELIK MY, GEDIK EO, et al. Tumor budding as a potential prognostic marker in determining the behavior of primary liver cancers[J]. World J Hepatol, 2023, 15( 6): 775- 785. DOI: 10.4254/wjh.v15.i6.775.
[36]	SHAFIQ AM, TAHA NA, ZAKY AH, et al. Prognostic significance of the tumor budding and tumor-infiltrating lymphocytes in survival of hepatocellular carcinoma patients[J]. Int J Health Sci(Qassim), 2024, 18( 6): 10- 19.
[37]	MONDAL S, ADHIKARI N, BANERJEE S, et al. Matrix metalloproteinase-9(MMP-9) and its inhibitors in cancer: A minireview[J]. Eur J Med Chem, 2020, 194: 112260. DOI: 10.1016/j.ejmech.2020.112260.
[38]	FUERST R, CHOI JY, KNAPINSKA AM, et al. Development of a putative Zn²⁺-chelating but highly selective MMP-13 inhibitor[J]. Bioorg Med Chem Lett, 2022, 76: 129014. DOI: 10.1016/j.bmcl.2022.129014.
[39]	SANYAL S, AMIN SA, BANERJEE P, et al. A review of MMP-2 structures and binding mode analysis of its inhibitors to strategize structure-based drug design[J]. Bioorg Med Chem, 2022, 74: 117044. DOI: 10.1016/j.bmc.2022.117044.
[40]	CHEN C, ZHAO SJ, KARNAD A, et al. The biology and role of CD44 in cancer progression: Therapeutic implications[J]. J Hematol Oncol, 2018, 11( 1): 64. DOI: 10.1186/s13045-018-0605-5.
[41]	MA ZL, GUO DL, WANG QX, et al. Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in hepatocellular carcinoma[J]. Theranostics, 2019, 9( 10): 2967- 2983. DOI: 10.7150/thno.30562.
[42]	XIA LZ, OYANG L, LIN JG, et al. The cancer metabolic reprogramming and immune response[J]. Mol Cancer, 2021, 20( 1): 28. DOI: 10.1186/s12943-021-01316-8.
[43]	LI ZZ, SUN CJ, QIN ZH. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming[J]. Theranostics, 2021, 11( 17): 8322- 8336. DOI: 10.7150/thno.62378.
[44]	ALAWYIA B, CONSTANTINOU C. Hepatocellular carcinoma: A narrative review on current knowledge and future prospects[J]. Curr Treat Options Oncol, 2023, 24( 7): 711- 724. DOI: 10.1007/s11864-023-01098-9.